Omni Bridgeway has moved on two distinct fronts in recent weeks, pairing a first-of-its-kind pro bono disbursement facility for migrant domestic workers in Asia with a high-profile commercial commitment to fund iyO Inc.'s intellectual property and trade secret suit against OpenAI, Sam Altman, and Sir Jony Ive. Taken together, the announcements showcase the breadth of the ASX-listed funder's pipeline — from access-to-justice initiatives at one end to flagship technology disputes at the other.

According to a joint Omni Bridgeway announcement, the funder has partnered with Hong Kong–based NGO Justice Without Borders to launch a "recycling" disbursement fund that covers court fees, expert reports, translation services, and court-ordered security for costs deposits in cross-border employment claims brought by migrant domestic workers across Hong Kong, Singapore, Indonesia, and other jurisdictions where JWB operates. The structure is designed so that recoveries are routed back into the facility, allowing each dollar of capital to support multiple claims over time. JWB executive director Celine Chan framed the initiative around the principle that "justice should not stop at a border or depend on ability to afford court fees," while Omni Bridgeway's Mitchell Dearness said the facility "fills a critical gap by covering costs that pro bono representation alone cannot address." The fund's headline commitment was not disclosed.

On the commercial side, according to a PR Newswire announcement from iyO, Omni Bridgeway is now backing iyO's federal litigation against OpenAI, Sam Altman, Jony Ive, io Products Inc., and former io co-founder Tang Yew Tan in the U.S. District Court for the Northern District of California (Case No. 25-cv-04861-TLT). iyO, a Google X spinout developing screenless, voice-controlled ear-worn devices, alleges trademark infringement of its federally registered "IYO" mark and trade secret misappropriation under both the California Uniform Trade Secrets Act and the federal Defend Trade Secrets Act over OpenAI's use of the "io" brand and the conduct of the io team after its acquisition. U.S. District Judge Trina L. Thompson granted a preliminary injunction in April 2026 finding iyO "likely to succeed on the merits of its trademark claim," after the Ninth Circuit affirmed an earlier temporary restraining order in December 2025. Trade-secret claims were added in March 2026.

For Omni Bridgeway, the two announcements land at a moment when public-market funders are working to demonstrate both portfolio breadth and capital efficiency to investors and clients. The recycling fund extends the firm's brand into access-to-justice territory long associated with NGOs and pro bono law firms, while the iyO matter places it directly into the most closely watched generative-AI dispute on the docket — a posture that allows Omni Bridgeway to argue, simultaneously, that litigation finance can democratize cross-border employment claims and underwrite the bet-the-product cases that define the next era of technology competition.

AIM-listed litigation funder Litigation Capital Management has secured a one-month extension of its debt covenant waiver from senior lender Northleaf to June 30, 2026, while disclosing negative developments in two case investments and warning that material write-downs will be reflected in upcoming financial statements.

According to a Litigation Capital Management regulatory announcement, the waiver continues on existing terms, with interest on the Northleaf facility remaining elevated by 2.00 percentage points per annum and no additional waiver fee charged. The two affected investments account for approximately A$9 million in invested capital between them; LCM did not identify the specific funded matters but said the negative outcomes will require material write-downs in its forthcoming results.

The funder added that the strategic review initiated in September 2025 remains ongoing and that the waiver extension reflects Northleaf's "ongoing support while LCM works towards a long-term resolution of its capital position." LCM's London-listed shares fell roughly 13% on the news.

The update is the latest in a sequence of capital-stack adjustments and adverse case developments that have weighed on LCM since late 2025, and reinforces the operating reality that publicly traded funders face: portfolio-level returns can be overwhelmed at the equity line by a small number of high-conviction matters that resolve adversely. With the waiver now tied to a June 30 deadline, the next four weeks are likely to determine both the contours of the strategic review and the terms of any new lender arrangement.